CN1649588A - 基于抗胆碱能药物及pde－iv抑制剂的新颖药物组合物 - Google Patents

基于抗胆碱能药物及pde－iv抑制剂的新颖药物组合物 Download PDF

Info

Publication number
CN1649588A
CN1649588A CNA02805346XA CN02805346A CN1649588A CN 1649588 A CN1649588 A CN 1649588A CN A02805346X A CNA02805346X A CN A02805346XA CN 02805346 A CN02805346 A CN 02805346A CN 1649588 A CN1649588 A CN 1649588A
Authority
CN
China
Prior art keywords
micrograms
acid
sucked
pharmaceutical composition
suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA02805346XA
Other languages
English (en)
Chinese (zh)
Inventor
克里斯托弗·J·M·米德
米歇尔·佩雷特
迈克尔·P·皮珀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of CN1649588A publication Critical patent/CN1649588A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA02805346XA 2001-03-07 2002-02-26 基于抗胆碱能药物及pde－iv抑制剂的新颖药物组合物 Pending CN1649588A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10110772A DE10110772A1 (de) 2001-03-07 2001-03-07 Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
DE10110772.2 2001-03-07

Publications (1)

Publication Number Publication Date
CN1649588A true CN1649588A (zh) 2005-08-03

Family

ID=7676493

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA02805346XA Pending CN1649588A (zh) 2001-03-07 2002-02-26 基于抗胆碱能药物及pde－iv抑制剂的新颖药物组合物

Country Status (18)

Country Link
EP (1) EP1372649B1 (enExample)
JP (1) JP2004521134A (enExample)
KR (1) KR20030081501A (enExample)
CN (1) CN1649588A (enExample)
AR (1) AR034213A1 (enExample)
AU (1) AU2002257587B2 (enExample)
BR (1) BR0207883A (enExample)
CA (1) CA2439763C (enExample)
CZ (1) CZ20032635A3 (enExample)
DE (1) DE10110772A1 (enExample)
EA (1) EA009989B1 (enExample)
HU (1) HUP0400782A3 (enExample)
IL (2) IL157326A0 (enExample)
MX (1) MXPA03008045A (enExample)
NZ (1) NZ528621A (enExample)
PL (1) PL363078A1 (enExample)
TW (1) TWI332833B (enExample)
WO (1) WO2002069945A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013177880A1 (zh) * 2012-05-28 2013-12-05 海南卫康制药(潜山)有限公司 复方盐酸氨溴索组合物及其制备方法
CN105358077A (zh) * 2013-05-31 2016-02-24 因西坡设备公司 髋臼扩孔钻组件

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
MXPA03010791A (es) * 2001-05-25 2004-03-02 Boehringer Ingelheim Pharma Combinacion de inhibidor de pde4 y tiotropio a sus derivados para tratamiento de enfermedades obstructivas de vias respiratorias y de otras enfermedades inflamatorias.
GB0118373D0 (en) * 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
US20030235538A1 (en) 2002-04-09 2003-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for the administration of an anticholinergic by inhalation
DE10230769A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren
US20060189642A1 (en) * 2003-03-28 2006-08-24 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
WO2004084894A1 (en) * 2003-03-28 2004-10-07 Altana Pharma Ag Synergistic combination comprising roflumilast and revatropate for the treatment of respiratory diseases
SI1610787T1 (sl) * 2003-03-28 2008-06-30 Nycomed Gmbh Sinergistična kombinacija, ki obsega roflumilastin antiholinergično sredstvo, izbrano izmed tiotropijevih soli, za zdravljenje respiratornih bolezni
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
CA2533786A1 (en) * 2003-07-28 2005-02-17 Boehringer Ingelheim International Gmbh Medicaments comprising pde iv inhibitors and a novel anticholinergic and their use for treating respiratory disorders
US7071333B2 (en) 2003-07-30 2006-07-04 Bristol-Myers Squibb Company Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
EP1504756A1 (en) * 2003-08-06 2005-02-09 Kyowa Hakko Kogyo Co., Ltd Medicament compositions comprising a heterocyclic compound and an anticholinergic
CA2547394A1 (en) * 2004-01-09 2005-07-28 Boehringer Ingelheim International Gmbh New pharmaceutical compositions based on a scopineester and nicotinamide derivatives
WO2005074982A2 (en) * 2004-02-06 2005-08-18 Meda Pharma Gmbh & Co. Kg Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases
PT1713473E (pt) 2004-02-06 2013-05-13 Meda Pharma Gmbh & Co Kg Combinação de anticolinérgicos e glucocorticóides para o tratamento a longo prazo de asma e copd
EP1713472A2 (en) * 2004-02-06 2006-10-25 MEDA Pharma GmbH & Co. KG Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids
WO2005082361A1 (en) * 2004-02-27 2005-09-09 Altana Pharma Ag Roflumilast and glycopryrronium combination
EP1616567A1 (en) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
ES2570332T3 (es) 2005-03-16 2016-05-17 Meda Pharma Gmbh & Co Kg La combinación de anticolinérgicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias
GB0521563D0 (en) 2005-10-21 2005-11-30 Glaxo Group Ltd Novel compounds
NZ568349A (en) 2005-12-21 2011-05-27 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
DK2046787T3 (da) 2006-08-01 2011-07-18 Glaxo Group Ltd Pyrazolo[3,4-B]pyridin-forbindelser, og deres anvendelse som PDE4-inhibitorer
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
CA2749403A1 (en) 2009-01-13 2010-09-02 Glaxo Group Limited Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
WO2012025473A1 (en) 2010-08-24 2012-03-01 Glaxo Group Limited Cc.chemokine receptor 4 antagonists
WO2012025474A1 (en) 2010-08-24 2012-03-01 Glaxo Group Limited Indazole compounds
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
JP6560986B2 (ja) 2013-03-15 2019-08-14 ヴェローナ ファーマ ピーエルシー 複合製剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000198734A (ja) * 1998-12-30 2000-07-18 Pfizer Inc 胃運動性減弱および関連疾患の治療のための運動性増強薬
MY134008A (en) * 1999-12-22 2007-11-30 Merck Frosst Canada Inc Subtituted 8-arylquinoline phospohodiestrase-4 inhibitors
WO2001057025A1 (en) * 2000-01-31 2001-08-09 Pfizer Products Inc. Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
CA2404226A1 (en) * 2000-03-23 2001-09-27 Takeda Chemical Industries, Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
US20020052312A1 (en) * 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
AR029984A1 (es) * 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013177880A1 (zh) * 2012-05-28 2013-12-05 海南卫康制药(潜山)有限公司 复方盐酸氨溴索组合物及其制备方法
CN105358077A (zh) * 2013-05-31 2016-02-24 因西坡设备公司 髋臼扩孔钻组件

Also Published As

Publication number Publication date
CZ20032635A3 (cs) 2004-09-15
BR0207883A (pt) 2004-07-27
AU2002257587B2 (en) 2007-05-10
KR20030081501A (ko) 2003-10-17
JP2004521134A (ja) 2004-07-15
HUP0400782A3 (en) 2012-09-28
EA200300929A1 (ru) 2004-04-29
EP1372649A2 (de) 2004-01-02
EP1372649B1 (de) 2012-07-25
HUP0400782A2 (hu) 2004-07-28
MXPA03008045A (es) 2003-12-04
CA2439763A1 (en) 2002-09-12
IL157326A (en) 2011-12-29
DE10110772A1 (de) 2002-09-12
WO2002069945A3 (de) 2003-01-30
IL157326A0 (en) 2004-02-19
EA009989B1 (ru) 2008-04-28
NZ528621A (en) 2005-04-29
WO2002069945A2 (de) 2002-09-12
TWI332833B (en) 2010-11-11
AR034213A1 (es) 2004-02-04
CA2439763C (en) 2012-10-16
PL363078A1 (en) 2004-11-15

Similar Documents

Publication Publication Date Title
CN1649588A (zh) 基于抗胆碱能药物及pde－iv抑制剂的新颖药物组合物
CN1678318A (zh) 以替托品盐和沙美特罗盐为基础的新的药物组合物
JP4537652B2 (ja) 抗コリン作用薬及びシクレソニドをベースとする新規薬剤組成物
JP2004517942A (ja) ほとんど副作用を伴わないβ様物質を含む医薬組成物
CN1688308A (zh) 含有与皮质类固醇和倍他米美类药物结合的新抗胆碱酯酶药的吸入性药物
CN1674887A (zh) 含抗胆碱能剂的吸入用的气雾剂制剂
US20020122773A1 (en) Pharmaceutical compositions based on anticholinergics and dopamine agonists
CN1646126A (zh) 包含类固醇及新颖抗胆碱酯酶剂的药物
CN1309378C (zh) 包含噻托铵盐的用于吸入的气雾制剂
CN1237970C (zh) 含提欧川平盐的溶液的可吸入制剂
AU2002221738B2 (en) Inhalative solution formulation containing a tiotropium salt
US20060110329A1 (en) Inhalable pharmaceutical compositions containing an anticholinergic, salmeterol, and a steroid
JP2004512379A (ja) 新規医薬組成物
JP2009514933A (ja) 吸入用エアロゾル製剤
US20060110330A1 (en) Inhalable pharmaceutical compositions containing an anticholinergic, formoterol, and a steroid
CA2738616A1 (en) Aerosol formulation for the inhalation of beta agonists
HK1080736A (en) Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors
CA2738617A1 (en) Aerosol formulation for the inhalation of beta agonists
HK1085119A (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
HK1078794A (en) Medicaments containing steroids and a novel anticholinesterase drug
JP2004516264A (ja) 抗コリン作用薬及びドーパミンアゴニストをベースとする新規医薬組成物
HK1078872A (en) Medicaments containing betamimetic drugs and a novel anticholinesterase drug
HK1084869A (en) Inhalation medicaments containing a novel anticholinesterase drug in conjunction with corticosteroids and betamimetic drugs
HK1060569B (en) Inhalative solution formulation containing a tiotropium salt
HK1078793B (en) Aerosol formulation for inhalation comprising a tiotropium salt

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1080736

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1080736

Country of ref document: HK